Rigel Pharmaceuticals, Inc. (RIGL) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Rigel Pharmaceuticals, Inc. (RIGL)

RIGL 34.52

-1.9%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (10)	4/8/2001 5:33:09 PM
From: tuck	of 566

Wilder, Shall we continue slinging abstracts at each other? Via MedLine: >>Dominant effector genetics in mammalian cells. Nat Genet 2001 Jan;27(1):23-9 (ISSN: 1061-4036) Xu X; Leo C; Jang Y; Chan E; Padilla D; Huang BC; Lin T; Gururaja T; Hitoshi Y; Lorens JB; Anderson DC; Sikic B; Luo Y; Payan DG; Nolan GP [Find other articles with these Authors] Rigel, Inc., San Francisco, California, USA. xxu@rigel.com. We have expressed libraries of peptides in mammalian cells to select for trans-dominant effects on intracellular signaling systems. As an example-and to reveal pharmacologically relevant points in pathways that lead to Taxol resistance-we selected for peptide motifs that confer resistance to Taxol-induced cell death. Of several peptides selected, one, termed RGP8.5, was linked to upregulation of expression of the gene ABCB1 (also known as MDR1, for multiple drug resistance) in HeLa cells. Our data indicate that trans-dominant effector peptides can point to potential mechanisms by which signaling systems operate. Such tools may be useful in functional genomic analysis of signaling pathways in mammalian disease processes.<< snip Nibbled a few hundred Friday. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next